Sonnet Biotherapeutics is a biotechnology business based in the US. Sonnet Biotherapeutics shares (SONN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.71 – an increase of 17.98% over the previous week. Sonnet Biotherapeutics employs 12 staff and has a trailing 12-month revenue of around $55,881.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $5.71 |
|---|---|
| 52-week range | $4.37 - $18.72 |
| 50-day moving average | $6.08 |
| 200-day moving average | $10.64 |
| Wall St. target price | $148.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-0.96 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $5.91 from 2024-10-18
| 1 week (2024-10-15) | 22.11% |
|---|---|
| 1 month (2024-09-20) | 491.00% |
| 3 months (2024-07-22) | 588.01% |
| 6 months (2024-04-22) | 248.67% |
| 1 year (2023-10-20) | 149.37% |
|---|---|
| 2 years (2022-10-21) | 405.13% |
| 3 years (2021-10-22) | 868.85% |
| 5 years (2019-10-22) | 19.24 |
| Revenue TTM | $55,881 |
|---|---|
| Gross profit TTM | $-21,094,076 |
| Return on assets TTM | -96.93% |
| Return on equity TTM | -264.57% |
| Profit margin | 0% |
| Book value | $4.01 |
| Market Capitalization | $3.7 million |
TTM: trailing 12 months
We're not expecting Sonnet Biotherapeutics to pay a dividend over the next 12 months.
Sonnet Biotherapeutics's shares were split on a 1:8 basis on 29 September 2024 . So if you had owned 8 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sonnet Biotherapeutics shares – just the quantity. However, indirectly, the new 700% higher share price could have impacted the market appetite for Sonnet Biotherapeutics shares which in turn could have impacted Sonnet Biotherapeutics's share price.
Over the last 12 months, Sonnet Biotherapeutics's shares have ranged in value from as little as $4.37 up to $18.7192. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sonnet Biotherapeutics's is 1.004. This would suggest that Sonnet Biotherapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Sonnet BioTherapeutics Holdings, Inc. , a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.